Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation



Rox PharmacySponsored by RoxPharmacy.com - Online Pharmacy, an pharmacy online supplies more than 500 quality generic products, free prescription, worldwide shipping.
xanax

Online Canadian Pharmacy canada pharmacy
Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • LinkedIn
  • Live
  • StumbleUpon
  • Yahoo! Buzz
  • Slashdot
  • Technorati
  • MSN Reporter

Related posts:

  1. Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
  2. Alkermes Initiates Phase 2 Clinical Study Of ALKS 33 For The Treatment Of Alcohol Dependence
  3. Alkermes Announces Positive Results From Two Clinical Trials Of ALKS 33